Publication details
Bezinterferonová léčba hepatitidy C
| Title in English | Possibilities of IFN-free therapy of hepatitis C |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | chronic hepatitis C; sofosbuvir; ledipasvir; velpatasvir; paritaprevir; ombitasvir; dasabuvir; elbasvir; grazoprevir |
| Description | Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100%), minimum contraindications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir +- dasabuvir. Fixed combinaton of elbasvir and grazoprevir is already available in some countries of the world. |